Cargando…

Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH

IL11 is important for fibrosis in non-alcoholic steatohepatitis (NASH) but its role beyond the stroma in liver disease is unclear. Here, we investigate the role of IL11 in hepatocyte lipotoxicity. Hepatocytes highly express IL11RA and secrete IL11 in response to lipid loading. Autocrine IL11 activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Jinrui, Viswanathan, Sivakumar, Adami, Eleonora, Singh, Brijesh K., Chothani, Sonia P., Ng, Benjamin, Lim, Wei Wen, Zhou, Jin, Tripathi, Madhulika, Ko, Nicole S. J., Shekeran, Shamini G., Tan, Jessie, Lim, Sze Yun, Wang, Mao, Lio, Pei Min, Yen, Paul M., Schafer, Sebastian, Cook, Stuart A., Widjaja, Anissa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782504/ https://www.ncbi.nlm.nih.gov/pubmed/33397952 http://dx.doi.org/10.1038/s41467-020-20303-z

Ejemplares similares

Hepatocyte Specific gp130 Signalling Underlies APAP Induced Liver Injury
por: Dong, Jinrui, et al.
Publicado: (2022)

Similarities and differences between IL11 and IL11RA1 knockout mice for lung fibro-inflammation, fertility and craniosynostosis
por: Ng, Benjamin, et al.
Publicado: (2021)

Molecular Dissection of Pro-Fibrotic IL11 Signaling in Cardiac and Pulmonary Fibroblasts
por: Widjaja, Anissa A., et al.
Publicado: (2021)

IL11 stimulates ERK/P90RSK to inhibit LKB1/AMPK and activate mTOR initiating a mesenchymal program in stromal, epithelial, and cancer cells
por: Widjaja, Anissa A., et al.
Publicado: (2022)

IL11 Activates Pancreatic Stellate Cells and Causes Pancreatic Inflammation, Fibrosis and Atrophy in a Mouse Model of Pancreatitis
por: Ng, Benjamin, et al.
Publicado: (2022)

Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease
por: Widjaja, Anissa A., et al.
Publicado: (2022)

IL11 Stimulates IL33 Expression and Proinflammatory Fibroblast Activation across Tissues
por: Widjaja, Anissa A., et al.
Publicado: (2022)

Targeting bile acids and lipotoxicity for NASH treatment
por: Chiang, John Y. L.
Publicado: (2017)

The pro-regenerative effects of hyperIL6 in drug-induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling
por: Dong, Jinrui, et al.
Publicado: (2021)

Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression
por: Zhou, Jin, et al.
Publicado: (2022)

Widespread Translational Control of Fibrosis in the Human Heart by RNA-Binding Proteins
por: Chothani, Sonia, et al.
Publicado: (2019)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond
por: Mahlapuu, Margit, et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Targeting Extracellular RNA Mitigates Hepatic Lipotoxicity and Liver Injury in NASH
por: Tewari, Archana, et al.
Publicado: (2023)

IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts
por: Adami, Eleonora, et al.
Publicado: (2021)

Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
por: Li, Songtao, et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Characterization of regulatory transcriptional mechanisms in hepatocyte lipotoxicity
por: Pérez-Schindler, Joaquín, et al.
Publicado: (2022)

Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy
por: Widjaja, Anissa A., et al.
Publicado: (2020)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
por: Rada, Patricia, et al.
Publicado: (2020)

HepatocyteGHR/STAT5b Signaling Protects Against Liver Injury in NAFLD/NASH Mice Models Independent of Steatosis
por: del Río-Moreno, Mercedes, et al.
Publicado: (2021)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Lotus Seedpod Extracts Reduced Lipid Accumulation and Lipotoxicity in Hepatocytes
por: Liu, Yen-Tze, et al.
Publicado: (2019)

Metabolic Changes of Hepatocytes in NAFLD
por: Lu, Qianrang, et al.
Publicado: (2021)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_548jric98rmeem1b4nadpeieig